weighing up the pros and cons of car-t therapy and bispecific antibodies in r/r dlbcl
Published 1 year ago • 50 plays • Length 2:38Download video MP4
Download video MP3
Similar videos
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
4:27
the possibility of combining car-t therapy and bispecific antibodies in the treatment of nhl
-
6:38
comparison of the safety & efficacy of car-t therapy vs bispecifics in r/r multiple myeloma
-
12:15
car-t vs bispecific antibodies for lymphoma
-
1:14
the car t-cell strategy vs bispecific antibodies
-
1:58
patient-reported outcomes vs performance-based metrics: the effects of car-t therapy on cognition
-
4:01
what are the differences between car t-cell therapy and bispecific antibodies?
-
2:52
replacing asct: car-t or bispecific antibodies?
-
19:39
t-cell engagers: targets, challenges and opportunity
-
4:22
icount 3ts - 3 part hematology system 7 reasons for you to choose ! 70 tests per hour !
-
5:52
chimeric antigen receptor (car) / car-t
-
2:22
combining car-ts & bispecific antibodies
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
2:05
the cost-effectiveness of car t-cell therapy
-
7:40
immunotherapy for aml and all: checkpoint inhibitors & car t-cells for b-cell all
-
1:53
phe885, a t-charge manufactured bcma-directed car-t therapy in r/r myeloma
-
1:33
patient selection for car-t in all
-
3:33
determining the optimal sequencing of bispecifics and car-t cells in patients with myeloma
-
3:36
cost-effectiveness of car t-cell therapy
-
0:46
scaling up car-t manufacturing with automation and digitalization
-
1:35
key mechanisms of resistance to car t-cell therapy
-
0:59
identifying molecular markers for the prediction of icaht in patients receiving car t-cell therapy